7 +/- 332.3 and 432.5 +/- 589.0 (vs baseline p = 0.318 and 0.033, respectively). After antimuscarinic treatment the nerve growth factor-to-creatinine and brain-derived neurotrophic factor-to-creatinine ratios further decreased to a mean of 179.8 +/- 237.9 and 146.6 +/- 264.9 (vs baseline p = 0.008 and < 0.001, respectively). There was no significant variation in the glial cell line-derived neurotrophic factor-to-creatinine ratio at any time point. The reduction in the number of urgency episodes per
week correlated with the brain-derived neurotrophic factor-to-creatinine variation (Pearson product-moment correlation coefficient r = 0.607, p = 0.006) but not with the nerve growth factor-to-creatinine ratio (r = 0.396, PD0332991 concentration p = 0.094).
Conclusions: The urinary nerve growth factor-to-creatinine and brain-derived neurotrophic factor-to-creatinine ratios are increased in patients with overactive bladder. These findings may have pathophysiological and clinical implications.”
“Objective: Previous studies have shown that the accumulation level of FMAU in tumor is proportional to its proliferation rate. This study demonstrated that 2′-deoxy-2′-[F-18]fluoro-beta-D-arabinofuranosyluracil
([F-18] FMAU) is a promising PET probe for noninvasively monitoring the therapeutic efficacy of 6% PEGylated liposomal vinorelbine (lipo-VNB) in a subcutaneous murine NG4TL4 sarcoma mouse model.
Methods: Female syngenic FVB/N mice were inoculated with NG4TL4 cells in the right flank. After tumor size reached 150 +/- 50 mm(3) (day 0), lipo-VNB (5 mg/kg) 4SC-202 in vitro Pritelivir in vivo was intravenously administered on days 0, 3 and 6. To monitor the therapeutic efficacy of lipo-VNB, [F-18]FMAU PET was employed
to evaluate the proliferation rate of tumor, and it was compared with that observed from [F-18]FDG/[F-18]fluoroacetate PET. The expression of proliferating cell nuclear antigen (PCNA) in tumor during treatment was determined by semiquantitative analysis of immunohistochemical staining.
Results: A significant inhibition (p <0.001) in tumor growth was observed on day 3 after a single dose treatment. The tumor-to-muscle ratio (TIM) derived from [18FWMAU-PET images of lipo-VNB-treated group declined from 2.33 +/- 0.16 to 1.26 +/- 0.03 after three doses of treatment, while that of the control remained steady. The retarded proliferation rate of lipo-VNB-treated sarcoma was confirmed by PCNA immunohistochemistry staining. However, both [F-18]FDG and [F-18]fluoroacetate microPET imaging did not show significant difference in TIM between the therapeutic and the control groups throughout the entire experimental period.
Conclusion: Lipo-VNB can effectively impede the growth of NG4TL4 sarcoma. [F-18]FMAU PET is an appropriate modality for early monitoring of the tumor response during the treatment course of lipo-VNB. (C) 2013 Elsevier Inc. All rights reserved.